Date:	20221121
Your Name:	Rongrong Qin
Manuscript	Title:_Influence of immunosuppressive drugs on NK cells in therapeutic drug exposure in liver
transplantat	tion
Manuscript	number (if known): HBSN-22- <u>438</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.)	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
	No time limit for this item.	the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3 R	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Rongrong Qin</u> I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:	20221121
Your Name:	:Jiwei Qin
Manuscript	Title:_Influence of immunosuppressive drugs on NK cells in therapeutic drug exposure in liver
transplanta ⁻	tion
Manuscript	number (if known): HBSN-22- <u>438</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
		the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3 R	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Jiwei Qin</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	20221121
Your Name	e:Xuefeng Li
Manuscrip	t Title: <u>Influence of immunosuppressive drugs on NK cells in therapeutic drug exposure in live</u>
transplanta	ation
Manuscrip	t number (if known): HBSN-22- 438

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.)	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
	No time limit for this item.	the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3 R	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Xuefeng Li</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	20221121
Your Name	:Zhijun Xu
Manuscript	t Title:_Influence of immunosuppressive drugs on NK cells in therapeutic drug exposure in liver
transplanta	ation
Manuscript	t number (if known): HBSN-22- 438

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

_		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.)	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
	No time limit for this item.	the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3 R	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Zhijun Xu</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

 Date:
 20221121

 Your Name:
 Peiqi He

 Manuscript Title:
 Influence of immunosuppressive drugs on NK cells in therapeutic drug exposure in liver

 transplantation

 Manuscript number (if known):

 HBSN-22 438

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
		the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Peiqi He</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	20221121	
Your Name:	Xiaodong Yuan	
Manuscript	Title:_Influence of immunosuppre	ssive drugs on NK cells in therapeutic drug exposure in liver
transplantat	tion_	
Manuscript	number (if known): HBSN-22438	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.)	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
	No time limit for this item.	the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Xiaodong Yuan</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	202	21121		-					
Your Nan	ne:	Cheng Sun							
Manuscr	ipt Title:	Influence o	<u>f immunosup</u>	pressive drugs	on NK cell	s in therap	eutic drug	exposure in liv	ver
transplar	ntation								
Manuscr	ipt numl	per (if known)	: HBSN-22	438					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.)	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
	No time limit for this item.	the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Cheng Sun</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	20221121	
Your Nam	ie: Björn Nashan	_
Manuscrij	pt Title: <u>Influence of immunos</u> u	uppressive drugs on NK cells in therapeutic drug exposure in live
transplan	tation_	
Manuscri	pt number (if known): HBSN-22-	438

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Björn Nashan research start-up fund	Fund Number: 2018KYQ003RC2017001
	provision of study materials, medical writing, article processing charges, etc.)	the National Natural Science Foundation of China	Fund Number : #8202290021, #92169118, #91942310
	No time limit for this item.	the National Key Research and Development Program of China	Fund Number: #2021YFC2300600
		the Anhui Provincial Natural Science Foundation	Fund Number: #2008085J35
		the Fundamental Research Funds for the Central Universities	Fund Number: WK9110000055
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
	testimony		
7	Support for attending	None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

<u>Björn Nashan</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.